Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuropsychological effects of hydrocortisone substitution in partial adrenal insufficiency after TBI or SAH
2009-014909-14Phase 4Terminated
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydrocortisone in hypoadrenocorticism, traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) (2 arms), sponsored by Max Planck Institute of Psychiatry. Primary endpoint: Change in alertness (TAP). Started Jan 2010; status: terminated.
02
Drugs
hydrocortisone
03
Conditions
hypoadrenocorticismtraumatic brain injury (TBI)subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2009-014909-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014909-14.